Last updated on February 2020

FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study


Brief description of study

This clinical investigation is intended to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired.

Clinical Study Identifier: NCT03490201

Find a site near you

Start Over

Ronald Reagan UCLA Medical Center

Los Angeles, CA United States
  Connect »

Memorial Regional Hospital

Hollywood, FL United States
  Connect »

Emory University Hospital

Atlanta, GA United States
  Connect »

Texas Cardiac Arrhythmia

Austin, TX United States
  Connect »

VA Medical Center Minneapolis

Minneapolis, MN United States
  Connect »

WakeMed Hospital

Raleigh, NC United States
  Connect »

USC University Hospital

Los Angeles, CA United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Texas Heart Institute

Houston, TX United States
  Connect »

Memorial Hermann Hospital

The Woodlands, TX United States
  Connect »

IKEM

Prague, Czechia
  Connect »

St. Georges Hospital

London, United Kingdom
  Connect »

Broward General Medical Center

Fort Lauderdale, FL United States
  Connect »

University of Washington

Seattle, WA United States
  Connect »